Výsledky vyhledávání - "Kristell Marzin"

A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Autor: Martina Gahlemann, Alfredo Guillén-Del-Castillo, Michael Kreuter, Salome R. Mack, Mandy Avis, Sven Wind, Kristell Marzin, Madelon C. Vonk

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics, 47, 1, pp. 81-89
European Journal of Drug Metabolism and Pharmacokinetics, 47, 81-89
European Journal of Drug Metabolism and Pharmacokinetics
Scientia

Contains fulltext : 248967.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVES: Nintedanib is a tyrosine kinase inhibitor approved for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD), idiopathic pul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d885fd470f94326021448f10278f27b

Zobrazit plný text záznamu

Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic

Autor: Ulrike Tontsch-Grunt, Paula-Elena Traexler, Anke Baum, Hanny Musa, Kristell Marzin, Shaonan Wang, Francesca Trapani, Harald Engelhardt, Flavio Solca

Publikováno v: British journal of cancer. 127(3)

Background BET inhibitors have been tested in several clinical trials where, despite encouraging preclinical results, substantial clinical benefit in monotherapy remains limited. This work illustrates the translational challenges and reports new data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff07294034092aed37a32806a8fac2f
https://pubmed.ncbi.nlm.nih.gov/35444289

Zobrazit plný text záznamu

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Autor: Claudia Dallinger, Kristell Marzin, Sven Wind, Ulrike Schmid, Ralf Lotz, Matthias Freiwald, Peter Stopfer, Thomas Ebner

Publikováno v: Clinical Pharmacokinetics

Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e59789e9dbc71e8535edbbb6fd4b3d
https://doi.org/10.1007/s40262-019-00766-0

Zobrazit plný text záznamu

Abstract CT514: A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors

Autor: Elena Élez, Heinz-Josef Lenz, Maja de Jonge, Rona Yaeger, Toshihiko Doi, Linda Pronk, Michael Teufel, Kristell Marzin, Josep Tabernero

Publikováno v: Cancer Research. 82:CT514-CT514

Background: Ligand-dependent Wnt signaling, mediated by LRP5/6, is highly activated in a subset of solid tumors. Activation leads to accumulation of intracellular β-catenin and expression of β-catenin-dependent genes that promote cancer cell prolif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26cefd192958d185611c656e333873f3
https://doi.org/10.1158/1538-7445.am2022-ct514

Zobrazit plný text záznamu

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

Autor: Doreen Luedtke, Arvid Jungnik, Claudia Dallinger, Kristell Marzin, Ute von Wangenheim

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics. 43:533-541

Nintedanib is a substrate for p-glycoprotein which can impact bioavailability. We investigated the effects of ketoconazole, a p-glycoprotein inhibitor, and rifampicin, a p-glycoprotein inducer, on the pharmacokinetics of nintedanib. In the ketoconazo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb662ae3edfbe2560f0f3e74f8352d4
https://doi.org/10.1007/s13318-018-0467-9

Zobrazit plný text záznamu

Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study

Autor: Rüdiger Koenen, Klaus Peter Kammerer, Kristell Marzin, Mabrouk Elgadi, Fenglei Huang, Natalja Strelkowa, Anne-Marie Quinson, Sebastian Haertter

Publikováno v: The Journal of Clinical Pharmacology. 57:1305-1314

Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P-450 enzymes and multiple membrane transporters. The objective of this study was to evaluate the effect of steady-state falda

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::511013f139cb2c8bb00656fd358edd59
https://doi.org/10.1002/jcph.931

Zobrazit plný text záznamu

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

Autor: Claudia Dallinger, Peter Stopfer, Kristell Marzin, Rolf Kaiser, André Liesener, Dirk Trommeshauser

Publikováno v: The Journal of Clinical Pharmacology. 56:1387-1394

Nintedanib, a triple angiokinase inhibitor, has undergone clinical investigation for the treatment of solid tumors and idiopathic pulmonary fibrosis. Nintedanib (Vargatef(®) ) plus docetaxel is approved in the EU for the treatment of patients with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a73efeec1bdd05af736569792d7f86df
https://doi.org/10.1002/jcph.752

Zobrazit plný text záznamu

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

Autor: Antoine Hollebecque, Eric Deutsch, Kristell Marzin, Mahmoud Ould-Kaci, Jean-Charles Soria, Anas Gazzah, Rastislav Bahleda, Flavien Roux, Françoise Farace, N Amellal, Christophe Massard, Andrea Varga

Publikováno v: British Journal of Cancer

Background: This Phase I study evaluated continuous- and intermittent-dosing (every other week) of afatinib plus nintedanib in patients with advanced solid tumours. Methods: In the dose-escalation phase (n=45), maximum tolerated doses (MTDs) were det

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::894f26a5b887497bfd0714d9150d713c
https://doi.org/10.1038/bjc.2015.374

Zobrazit plný text záznamu

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Autor: David Schnell, Raimund Kuelzer, Gunther Kretschmar, Claudia Dallinger, Ulrike Schmid, Kristell Marzin, Doreen Luedtke, Rozsa Schlenker-Herceg, Sandrine Kraemer

Publikováno v: Journal of Clinical Pharmacology

Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non–small cell lung cancer and idiopathic pulmonary fibrosis (IPF). This phase 1 open‐label study investigated the influence of mild and moderate hepatic impair

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab38af1d971cc804850588f708ae44e
https://pubmed.ncbi.nlm.nih.gov/29106740

Zobrazit plný text záznamu

Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study

Autor: Fenglei, Huang, Kristell, Marzin, Rüdiger, Koenen, Klaus Peter, Kammerer, Natalja, Strelkowa, Mabrouk, Elgadi, Anne-Marie, Quinson, Sebastian, Haertter

Publikováno v: Journal of clinical pharmacology. 57(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f94feaa39a538049c67cd236536f5fbe
https://pubmed.ncbi.nlm.nih.gov/28513969

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání